Related Experiment Video
Updated: Jul 15, 2026
Microglia as a Surrogate Biosensor to Determine Nanoparticle Neurotoxicity
Published on: October 25, 2016
Polydopamine nanoparticles as immunomodulators: inhibition of M1 microglial polarization
Maria Cristina Ceccarelli1,2, Luigi Lai1,3, Alessio Carmignani1
1Istituto Italiano di Tecnologia, Smart Bio-Interfaces, Pontedera, Italy.
Abstract:
Neuroinflammation is a central feature of numerous neurodegenerative diseases, including Alzheimer's and Parkinson's disease, where excessive activation of microglia can contribute to neuronal damage. The pro-inflammatory M1 phenotype of microglia is characterized by increased production of reactive oxygen species (ROS), overexpression of surface markers such as CD40 and CD86, and secretion of cytokines like IL-6, IL-8, and TNF-α, all of which exacerbate oxidative stress and neurodegeneration. The development of strategies to control and tune microglial pro-inflammatory activation is therefore critical for reducing the progression of these conditions. In this study, the potential of polydopamine nanoparticles (PDNPs) as novel immunomodulatory agents for attenuating M1 microglial polarization was investigated. PDNPs were synthesized via a simple and reproducible protocol and thoroughly characterized in terms of size, morphology, hydrodynamic diameter, and surface charge, confirming their uniformity and stability. Biocompatibility assays showed that PDNPs are well tolerated by human microglial clone 3 (HMC3) cells, with minimal cytotoxicity even at relatively high concentrations. Confocal microscopy and flow cytometry analyses demonstrated efficient internalization of PDNPs by microglia, with preferential accumulation in lysosomal compartments and negligible mitochondrial localization. To mimic neuroinflammatory conditions, HMC3 cells were stimulated with interferon-gamma (IFN-γ), which significantly increased intracellular ROS levels, surface expression of CD40 and CD86, and secretion of pro-inflammatory cytokines. The co-treatment with PDNPs effectively mitigated these effects by reducing oxidative stress, suppressing the upregulation of M1 markers, and decreasing cytokine release, thereby preventing the shift toward a pro-inflammatory state. The results of this work demonstrate that PDNPs not only exhibit excellent biocompatibility and cellular uptake but also provide a robust means of counteracting IFN-induced microglial activation. These results establish PDNPs as promising nanoplatforms for modulating neuroinflammation and microglial activation. This study highlights the potential of PDNPs for future applications in the treatment of neurodegenerative diseases.
Insights
Polydopamine nanoparticles (PDNPs) effectively reduce harmful microglial activation in neuroinflammation models. This study shows PDNPs can be a promising therapeutic strategy for neurodegenerative diseases by controlling the M1 microglial phenotype.
Area of Science:
- Neuroscience
- Nanotechnology
- Immunology
Background:
- Neuroinflammation, driven by microglia, is key in neurodegenerative diseases like Alzheimer's and Parkinson's.
- The pro-inflammatory M1 microglial phenotype exacerbates neuronal damage through reactive oxygen species (ROS) and cytokine release.
- Targeting microglial activation is crucial for developing effective treatments for neurodegenerative conditions.
Purpose of the Study:
- To investigate polydopamine nanoparticles (PDNPs) as novel immunomodulatory agents for attenuating M1 microglial polarization.
- To assess the biocompatibility, cellular uptake, and efficacy of PDNPs in a neuroinflammatory model.
Main Methods:
- PDNPs were synthesized and characterized for size, morphology, and stability.
- Biocompatibility was evaluated using human microglial clone 3 (HMC3) cells.
- Neuroinflammation was induced in HMC3 cells with interferon-gamma (IFN-γ), and the effects of PDNP co-treatment were analyzed using confocal microscopy, flow cytometry, and assessment of ROS, surface markers (CD40, CD86), and cytokine secretion (IL-6, IL-8, TNF-α).
Main Results:
- PDNPs demonstrated excellent biocompatibility and efficient cellular uptake by microglia, localizing primarily in lysosomes.
- PDNP co-treatment significantly reduced IFN-γ-induced ROS production, suppressed M1 marker expression (CD40, CD86), and decreased pro-inflammatory cytokine secretion.
- PDNPs effectively counteracted the pro-inflammatory M1 microglial activation induced by IFN-γ.
Conclusions:
- PDNPs are biocompatible, readily internalized by microglia, and effective in mitigating M1 microglial polarization.
- PDNPs represent a promising nanoplatform for modulating neuroinflammation and offer potential therapeutic applications for neurodegenerative diseases.
